A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

Objectives. The aim of this study was to provide the first study to systematically analyze the efficacy and safety of PCSK9-mAbs in the treatment of familial hypercholesterolemia (FH). Methods. A computer was used to search the electronic Cochrane Library, PubMed/MEDLINE, and Embase databases for cl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xiaoyue Ge, Tiantian Zhu, Hao Zeng, Xin Yu, Juan Li, Shanshan Xie, Jinjin Wan, Huiyao Yang, Keke Huang, Weifang Zhang
Formato: article
Lenguaje:EN
Publicado: Hindawi Limited 2021
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/e51a44835611488ab7f48d477e25e3ac
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e51a44835611488ab7f48d477e25e3ac
record_format dspace
spelling oai:doaj.org-article:e51a44835611488ab7f48d477e25e3ac2021-11-08T02:35:46ZA Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia2314-614110.1155/2021/8032978https://doaj.org/article/e51a44835611488ab7f48d477e25e3ac2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/8032978https://doaj.org/toc/2314-6141Objectives. The aim of this study was to provide the first study to systematically analyze the efficacy and safety of PCSK9-mAbs in the treatment of familial hypercholesterolemia (FH). Methods. A computer was used to search the electronic Cochrane Library, PubMed/MEDLINE, and Embase databases for clinical trials using the following search terms: “AMG 145”, “evolocumab”, “SAR236553/REGN727”, “alirocumab”, “RG7652”, “LY3015014”, “RN316/bococizumab”, “PCSK9”, and “familial hypercholesterolemia” up to November 2020. Study quality was assessed with the Cochrane Collaboration’s tool, and publication bias was evaluated by a contour-enhanced funnel plot and the Harbord modification of the Egger test. After obtaining the data, a meta-analysis was performed using R software, version 4.0.3. Results. A meta-analysis was performed on 7 clinical trials (926 total patients). The results showed that PCSK9-mAbs reduced the LDL-C level by the greatest margin, WMD −49.14%, 95% CI: −55.81 to −42.47%, on FH versus control groups. PCSK9-mAbs also significantly reduced lipoprotein (a) (Lp (a)), total cholesterol (TC), triglycerides (TG), apolipoprotein-B (Apo-B), and non-high-density lipoprotein cholesterol (non-HDL-C) levels and increased HDL-C and apolipoprotein-A1 (Apo-A1) levels of beneficial lipoproteins. Moreover, no significant difference was found between PCSK9-mAbs treatment and placebo in common adverse events, serious events, and laboratory adverse events. Conclusion. PCSK9-mAbs significantly decreased LDL-C and other lipid levels with satisfactory safety and tolerability in FH treatment.Xiaoyue GeTiantian ZhuHao ZengXin YuJuan LiShanshan XieJinjin WanHuiyao YangKeke HuangWeifang ZhangHindawi LimitedarticleMedicineRENBioMed Research International, Vol 2021 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
spellingShingle Medicine
R
Xiaoyue Ge
Tiantian Zhu
Hao Zeng
Xin Yu
Juan Li
Shanshan Xie
Jinjin Wan
Huiyao Yang
Keke Huang
Weifang Zhang
A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
description Objectives. The aim of this study was to provide the first study to systematically analyze the efficacy and safety of PCSK9-mAbs in the treatment of familial hypercholesterolemia (FH). Methods. A computer was used to search the electronic Cochrane Library, PubMed/MEDLINE, and Embase databases for clinical trials using the following search terms: “AMG 145”, “evolocumab”, “SAR236553/REGN727”, “alirocumab”, “RG7652”, “LY3015014”, “RN316/bococizumab”, “PCSK9”, and “familial hypercholesterolemia” up to November 2020. Study quality was assessed with the Cochrane Collaboration’s tool, and publication bias was evaluated by a contour-enhanced funnel plot and the Harbord modification of the Egger test. After obtaining the data, a meta-analysis was performed using R software, version 4.0.3. Results. A meta-analysis was performed on 7 clinical trials (926 total patients). The results showed that PCSK9-mAbs reduced the LDL-C level by the greatest margin, WMD −49.14%, 95% CI: −55.81 to −42.47%, on FH versus control groups. PCSK9-mAbs also significantly reduced lipoprotein (a) (Lp (a)), total cholesterol (TC), triglycerides (TG), apolipoprotein-B (Apo-B), and non-high-density lipoprotein cholesterol (non-HDL-C) levels and increased HDL-C and apolipoprotein-A1 (Apo-A1) levels of beneficial lipoproteins. Moreover, no significant difference was found between PCSK9-mAbs treatment and placebo in common adverse events, serious events, and laboratory adverse events. Conclusion. PCSK9-mAbs significantly decreased LDL-C and other lipid levels with satisfactory safety and tolerability in FH treatment.
format article
author Xiaoyue Ge
Tiantian Zhu
Hao Zeng
Xin Yu
Juan Li
Shanshan Xie
Jinjin Wan
Huiyao Yang
Keke Huang
Weifang Zhang
author_facet Xiaoyue Ge
Tiantian Zhu
Hao Zeng
Xin Yu
Juan Li
Shanshan Xie
Jinjin Wan
Huiyao Yang
Keke Huang
Weifang Zhang
author_sort Xiaoyue Ge
title A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
title_short A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
title_full A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
title_fullStr A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
title_full_unstemmed A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
title_sort systematic review and meta-analysis of therapeutic efficacy and safety of alirocumab and evolocumab on familial hypercholesterolemia
publisher Hindawi Limited
publishDate 2021
url https://doaj.org/article/e51a44835611488ab7f48d477e25e3ac
work_keys_str_mv AT xiaoyuege asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT tiantianzhu asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT haozeng asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT xinyu asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT juanli asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT shanshanxie asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT jinjinwan asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT huiyaoyang asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT kekehuang asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT weifangzhang asystematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT xiaoyuege systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT tiantianzhu systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT haozeng systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT xinyu systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT juanli systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT shanshanxie systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT jinjinwan systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT huiyaoyang systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT kekehuang systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
AT weifangzhang systematicreviewandmetaanalysisoftherapeuticefficacyandsafetyofalirocumabandevolocumabonfamilialhypercholesterolemia
_version_ 1718443239683391488

Ejemplares similares